Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

NCT07132463 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

RADIATION: Long-course chemoradiotherapy
DRUG: Tislelizumab combined with the CAPOX regimen
DRUG: CAPOX regimen

Sponsor

Fudan University